Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors

Article ID	Journal	Published Year	Pages	File Type
10799781	Biochimica et Biophysica Acta (BBA) - General Subjects	2016	40 Pages	PDF

Abstract

We furnish fresh insights into gefitinib functions which may provide new molecular clues to its efficacy and safety issues.

Keywords

H1R forskolin H3R GPCR H4 receptor HDC TKI CML RTK Fsk PDE PEA H2R NFAT CRE HER2 H4R AML EGFR (R)-α-methylhistamine 2-pyridylethylamine cAMP G-protein coupled receptor Cyclic adenosine monophosphate Tyrosine kinase Gefitinib RAMH Cancer NSCLC Non-small cell lung cancer nuclear factor of activated T-cells cAMP response element Phosphodiesterase Acute myelogenous leukemia chronic myelogenous leukemia Tyrosine kinase inhibitor Histidine Decarboxylase H1 receptor H2 receptor H3 receptor Estrogen receptor alpha Receptor Tyrosine Kinase Human epidermal growth factor receptor 2 Epidermal growth factor receptor Histamine receptor

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry

Preview

Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors

Authors

Manisha Yadav, Abhishek Kumar Singh, Harish Kumar, Geeta Rao, Bandana Chakravarti, Anagha Gurjar, Shalini Dogra, Sapana Kushwaha, Achchhe Lal Vishwakarma, Prem Narayan Yadav, Dipak Datta, Anil Kumar Tripathi, Naibedya Chattopadhyay, Arun Kumar Trivedi,